Preemptive Analgesia With Celecoxib for Acute Dental Pain Management
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Mar 5, 2021
Trial Information
Current as of August 19, 2025
Completed
Keywords
ClinConnect Summary
This randomized, double-blind, placebo-controlled, prospective clinical trial is designed to compare the postoperative pain reduction of a single agent nonsteroidal anti-inflammatory drug (NSAID) and NSAID combination regimen administered preemptively. Subjects will be given a single oral dose of a cyclooxygenase-2 (COX-2) selective inhibitor (celecoxib 200mg), or celecoxib 200 mg in combination with acetaminophen (APAP 1000 mg) 30 to 60 minutes prior to the procedure. Oral surgery involving at least one impacted mandibular third molar will be performed using a combination of intravenous se...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • American Society of Anesthesiologists (ASA) physical status classification 1 or 2
- • at least 1 impacted mandibular third molar planned for extraction
- Exclusion Criteria:
- • ASA 3 or higher for physical status classification
- • severe pericoronitis associated with third molar to be extracted
- • any known allergies to NSAIDs, aspirin, acetaminophen, sulfa drugs
- • history of cardiovascular or cerebrovascular disease
- • hepatic disease or impairment
- • pregnancy
About The University Of Texas Health Science Center, Houston
The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Houston, Texas, United States
Patients applied
Trial Officials
Harry D Gilbert, DDS
Principal Investigator
University of Texas School of Dentistry at Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials